pharma · Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) · Advanced Solid Tumor
Daiichi Sankyo US
Daiichi Sankyo
Daiichi Sankyo US clinical programs — 22 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 211 Mt. Airy Road Basking Ridge, Basking Ridge, NJ 07920, US
- Employees
- 4,386
- Programs
- 58
- Drugs
- 66
- Patents
- 0
Daiichi Sankyo US projects
22 ClinicalTrials.gov programs sponsored by Daiichi Sankyo US.
Daiichi Sankyo US has 22 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
AC220-168
Daiichi Sankyo
Acute myeloid leukemia
1 trial -
CS-3150
Daiichi Sankyo
Hypertension
1 trial -
DS-8201a
Daiichi Sankyo
Advanced (unresectable or metastatic) human epidermal growth receptor 2 (HER2)-expressing/HER2-mutated solid tumors
1 trial -
DS1062-328
Daiichi Sankyo
Locally Advanced or Metastatic Urothelial Carcinoma
1 trial -
DS1062-A-U304
Daiichi Sankyo
Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
1 trial -
DS6000-109
Daiichi Sankyo
Platinum-resistant, high-grade serous ovarian cancer (OVC),high-grade endometrioid OVC, primary peritoneal cancer, or fallopian tube cancer
1 trial -
DS7300-188
Daiichi Sankyo
Small Cell Lung Cancer (SCLC)
1 trial -
DS7300-202
Daiichi Sankyo
Esophageal Squamous Cell Carcinoma (ESCC)
1 trial -
DS8201-724
Daiichi Sankyo
Unresectable, Locally Advanced or Metastatic HER2 positive Gastric or Gastroesophageal Junction Cancer
1 trial -
DS8201-772
Daiichi Sankyo
Ovarian Cancer
1 trial -
DS8201-793
Daiichi Sankyo
Unresectable or Metastatic HER2 overexpressing and PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer
1 trial -
DS8201-854
Daiichi Sankyo
HER2-expressing endometrial cancer (IHC 3+/2+)
1 trial -
DS8201-A-U302
Daiichi Sankyo
Metastatic breast cancer
1 trial -
DS8201-A-U305
Daiichi Sankyo
High-Risk HER2-Positive Breast Cancer
1 trial -
DS8201-A-U306
Daiichi Sankyo
Metastatic Gastric Adenocarcinoma
1 trial -
Datopotamab deruxtecan, DOCETAXEL
Daiichi Sankyo
Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
1 trial -
Edoxaban
Daiichi Sankyo
Cardiac Disease
1 trial -
Trastuzumab Deruxtecan
Daiichi Sankyo
Gastric Cancer
1 trial -
Trastuzumab Deruxtecan
Daiichi Sankyo
Non-small Cell Lung Cancer
1 trial -
Trastuzumab Deruxtecan
Daiichi Sankyo
Ovarian Cancer
1 trial -
U31402-A-U301
Daiichi Sankyo
Metastatic or Locally Advanced Epidermal Growth Factor Receptor-mutated (EGFRm) Non-small Cell Lung Cancer (NSCLC)
1 trial -
edoxaban tosylate(DU-176b)
Daiichi Sankyo
Venous Thromboembolism
1 trial
Frequently asked questions
How many clinical projects does Daiichi Sankyo US have?
22 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.